Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy
免疫治疗患者肿瘤及微环境的动态分析
基本信息
- 批准号:10705833
- 负责人:
- 金额:$ 19.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AftercareAgonistApoptosisB-Cell Antigen ReceptorB-Cell NeoplasmBioinformaticsBiological AssayBiomedical ResearchBiometryBiopsyBlood specimenCD4 Positive T LymphocytesCancer PatientCell CommunicationCell TherapyCellsClinicalClinical TrialsCollectionComplementComplexCore BiopsyDataData SetDevelopmentDistalDistantDoctor of PhilosophyEvolutionExhibitsExperimental ModelsFollicular LymphomaFutureGene ExpressionGene Expression ProfileGenerationsGenomicsGoalsHelper-Inducer T-LymphocyteHistologicHistologyHumanImmuneImmune responseImmune systemImmunologicsImmunologyImmunotherapyInflammatory ResponseInvestigationKnowledgeLinkLow Dose RadiationLymphomaMacrophageMalignant NeoplasmsMeasuresMentorsMinorityModernizationMusOX40OncologyPathway interactionsPatientsPhenotypePhosphotransferasesPhysiciansPopulationPre-Clinical ModelRegulatory T-LymphocyteResearchResearch PersonnelSamplingScientistSiteSumSurvivorsT cell clonalityT-Cell ActivationT-Cell ReceptorT-LymphocyteTechniquesTechnologyTestingTimeTrainingTravelTreatment EfficacyTumor ImmunityTumor TissueTumor-associated macrophagesUniversitiesVaccinationWorkanalytical methodanalytical toolanti-tumor immune responsebreast cancer survivalcancer cellcancer genomicscancer immunotherapycancer typecareer developmentcell typechemotherapycomplex dataeffector T cellexperiencefightinghigh dimensionalityimmune checkpoint blockadeimmune healthimmune stimulantimmunotherapy trialsimprovedin situ vaccinationinhibitorinnovationinsightlongitudinal analysismedical schoolsneoplastic cellnovelnovel therapeutic interventionpatient subsetspreclinical studyprogramsresearch and developmentresponseskillsspatial relationshiptooltranscriptometranscriptomicstreatment responsetumortumor microenvironment
项目摘要
PROJECT SUMMARY / ABSTRACT
Harnessing the immune system to fight cancer has proven to be remarkably effective, but most patients who
are treated with immunotherapy do not respond. Our understanding of what determines the response to
immunotherapy remains poor. Immune recognition and destruction of cancer cells occurs at the level of the
tumor microenvironment (TME), but the human TME has been difficult to study due to a lack of suitable
preclinical models, the challenges in acquiring adequate patient tumor tissues, and a lack of analytic tools to
study the complex interplay between cancer and the immune system. In this proposal, we will directly
investigate the changes immunotherapy produces in the TME of patients over time by utilizing samples from a
serial multi-site tumor biopsy approach in two trials of in situ vaccination (ISV) in follicular lymphoma. we are
leveraging technological advances in single cell genomics and multiparameter histology platforms to study
limited samples in great depth as well as bioinformatics advances that allow us to extract important information
from large complex datasets with a goal of identifying the key tumor-immune interactions before treatment and
the evolution of immune responses with treatment. We will focus on how T-cell phenotypes and clonotypes
change after ISV and relate to tumor responses (Aim 1), on whether tumor cell responses to ISV may enhance
the generation of anti-tumor immunity (Aim 2), and on interactions between cells in the TME (Aim 3). This
comprehensive approach will yield critical insights into the determinants of successful immunotherapy.
This work will be undertaken by Tanaya Shree, MD PhD, a fellow in the Department of Oncology at the
Stanford University School of Medicine. Dr. Shree completed a dual MD/PhD program at Cornell/ Rockefeller
University/ Sloan-Kettering where she discovered that tumor-associated macrophages helped murine breast
cancer survive chemotherapy and that dampening critical macrophage functions could improve chemotherapy
efficacy. At Stanford, Dr. Shree continues to investigate cancer and the immune system, having developed two
investigator-initiated immunotherapy trials, studied the immune health of lymphoma survivors, and established
expertise in immunology and high-dimensional assays for studying mechanisms of immunotherapy.
Dr. Shree will be mentored in this work by Ronald Levy, MD, and Hanlee Ji, MD. Both are physician-scientists
who have made significant contributions to the fields of cancer immunotherapy and genomics and have
mentored numerous successful independent researchers. In addition, a distinguished committee of advisors,
consisting of Drs. Crystal Mackall, Garry Nolan, and Ash Alizadeh, will guide her research and career
development. Dr. Shree’s training plan focuses on didactic and practical training in advanced immunology,
bioinformatics, and biostatistics to complement her substantial skills and experience in biomedical research.
项目总结/摘要
利用免疫系统对抗癌症已被证明是非常有效的,但大多数患者
免疫治疗没有反应。我们对决定反应的因素的理解
免疫治疗仍然很差。癌细胞的免疫识别和破坏发生在免疫系统的水平。
肿瘤微环境(TME),但人类TME一直难以研究,由于缺乏合适的
临床前模型,获取足够的患者肿瘤组织的挑战,以及缺乏分析工具,
研究癌症和免疫系统之间复杂的相互作用。在这份提案中,我们将直接
研究免疫治疗随时间推移在患者TME中产生的变化,
在滤泡性淋巴瘤原位接种(ISV)的两项试验中采用连续多部位肿瘤活检方法。我们
利用单细胞基因组学和多参数组织学平台的技术进步来研究
有限的样本,以及生物信息学的进步,使我们能够提取重要的信息,
从大型复杂数据集中,目标是在治疗前确定关键的肿瘤-免疫相互作用,
免疫反应的演变与治疗。我们将重点讨论T细胞表型和克隆型
肿瘤细胞对ISV的反应是否会增强
抗肿瘤免疫力的产生(目的2)以及TME中细胞之间的相互作用(目的3)。这
全面的方法将产生关键的见解成功的免疫治疗的决定因素。
这项工作将由Tanaya Shree,MD PhD,肿瘤学系研究员,
斯坦福大学医学院。Shree博士在康奈尔大学/洛克菲勒大学完成了双MD/PhD课程
大学/斯隆-凯特琳,她发现肿瘤相关的巨噬细胞有助于小鼠乳腺癌
癌症在化疗中存活下来,抑制关键的巨噬细胞功能可以改善化疗
功效在斯坦福大学,Shree博士继续研究癌症和免疫系统,
癌症患者发起的免疫治疗试验,研究了淋巴瘤幸存者的免疫健康,并建立了
在免疫学和研究免疫治疗机制的高维测定方面的专业知识。
博士Shree将由医学博士罗纳德利维和医学博士Hanlee Ji指导这项工作。两人都是医学科学家
他在癌症免疫治疗和基因组学领域做出了重大贡献,
指导了许多成功的独立研究人员。此外,一个杰出的顾问委员会,
由Crystal Mackall博士,Garry Nolan博士和Ash Alizadeh博士组成,将指导她的研究和职业生涯
发展Shree博士的培训计划侧重于高级免疫学的教学和实践培训,
生物信息学和生物统计学,以补充她在生物医学研究方面的丰富技能和经验。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity?
B 细胞缺陷患者能否依赖 COVID-19 疫苗诱导的 T 细胞免疫?
- DOI:10.1111/bjh.18210
- 发表时间:2022
- 期刊:
- 影响因子:6.5
- 作者:Shree,Tanaya
- 通讯作者:Shree,Tanaya
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tanaya Shree其他文献
Tanaya Shree的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tanaya Shree', 18)}}的其他基金
Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy
免疫治疗患者肿瘤及微环境的动态分析
- 批准号:
10652213 - 财政年份:2020
- 资助金额:
$ 19.02万 - 项目类别:
Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy
免疫治疗患者肿瘤及微环境的动态分析
- 批准号:
10039827 - 财政年份:2020
- 资助金额:
$ 19.02万 - 项目类别:
Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy
免疫治疗患者肿瘤及微环境的动态分析
- 批准号:
10247746 - 财政年份:2020
- 资助金额:
$ 19.02万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)